| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_247e501b647854aca7ff1baf9e587969 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C277-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C277-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
2021-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99bfdab68a467c435e4d6d02a345519f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02a053053787ca543f775b49507878d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92526654a997004ab063e62ce42f7fc6 |
| publicationDate |
2021-08-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102288679-B1 |
| titleOfInvention |
Co-crystal polymorphs of napamostat mesylate, and method for preparing the same |
| abstract |
The present invention relates to various co-crystalline nafamostat mesylate and a method for preparing the same, and is characterized in that it consists of nafamostat mesylate and a pharmaceutically acceptable crystalline phase. Napamostat mesylate co-crystal product of the present invention satisfies all requirements as an active ingredient of a pharmaceutical composition, and can be usefully used in pharmaceutical formulations. In addition, since the manufacturing process is simple and easy, commercial mass production is possible. |
| priorityDate |
2021-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |